The market's first reaction was unforgiving. Victrex's shares fell sharply after the update, as investors digested weaker volumes, lower revenues and cautious commentary from analysts. Yet the company insists that its long-term story remains intact.
A soft start, but no surprise
The headline numbers were underwhelming. Volumes fell by 4% year on year in the quarter ending December 31st, while revenue dropped by 6%. Average selling prices edged slightly lower. Some end-markets - notably transport, medical and value-added resellers - were subdued, though energy and industrial applications continued to grow.
Management was quick to stress that this wasn't unexpected. Victrex's business is seasonal, and the first quarter is usually the weakest. December was softer than usual, but January showed improvement. On a year-to-date basis, volumes are now back in line with last year.
More importantly, the company repeated its familiar refrain: performance this year will be weighted towards the second half. That reassurance, however, is wearing thin.
Victrex maintains 2026 guidance
Despite the shaky start, Victrex has left its full-year guidance unchanged. That is a bold stance, given that it also expects the first half of the year to be weaker than last year's.
The logic rests on two pillars. First, management expects demand to improve later in the year, as customer inventories normalise and activity picks up in key markets. Second, Victrex is rolling out a profit improvement plan aimed at simplifying its product portfolio, improving efficiency and cutting overheads.
The target is at least £10m of annualised cost savings by 2027, with some benefits appearing in the second half of 2026.
Analysts remain unconvinced
Scepticism is growing among analysts. Jefferies described the update as "challenging" and questions whether end-markets or pricing will recover enough this year. It expects Victrex's pre-tax profit to fall about 10% below market consensus. Citi is more neutral, accepting the "transitional year" narrative but acknowledging that volumes and pricing were weaker than expected.
The problem is credibility. Victrex has spoken before about second-half recoveries. Investors now want evidence, not assurances.
A birght spot lies in the balance sheet. Victrex ended December with modest net debt of just £21m and £28m of cash, even before paying a hefty final dividend. This financial strength gives management room to manoeuvre and patience to invest through the cycle.
The dividend, yielding around 4% at current share prices, also provides some support for long-term investors.
Valuation: quality at a discount?
After the recent share price drop, Victrex trades on valuation multiples that look more reasonable than in the past. The shares sit on a forward price-to-earnings ratio in the mid-teens, below their long-term average. For a company with high margins, strong intellectual property and exposure to structural growth markets, that is not demanding.
But cheap stocks are often cheap for a reason. Until volumes recover and the cost-saving plan delivers tangible results, the market is unlikely to re-rate the shares.
Victrex remains a high-quality business in attractive niches. Its materials are hard to replace, its customer relationships are deep, and its balance sheet is sound. Yet 2026 looks set to be a year of transition rather than transformation.
